The purpose of the study is to assess the potential benefits of ivonescimab as a second or third line of treatment for patients with relapsing pleural mesothelioma. Participants in the study will receive ivonescimab through an intravenous drip, which means the medication is delivered directly into the bloodstream. The study will also involve the use of standard chemotherapy as part of the treatment plan. The trial will last for a period of up to 24 months, during which the effects of the treatment will be closely monitored.

Throughout the study, researchers will evaluate how well the treatment controls the disease and monitor any side effects that may occur. The goal is to determine if ivonescimab can help manage pleural mesothelioma more effectively than current treatment options. This trial represents an important step in exploring new ways to treat this challenging condition and improve outcomes for patients.

The purpose of the study is to assess how well patients can complete this new treatment plan and whether it can make surgery possible for those who were initially considered inoperable. The study will involve two cycles of the combined chemotherapy and immunotherapy treatments. After these treatments, doctors will evaluate if the cancer has shrunk enough to allow for surgery. The study will also monitor the safety of the treatments and any side effects that may occur.

Participants in the study will be closely observed to see if the treatment helps them live longer without the cancer getting worse. The study will also look at the quality of life of the participants during and after the treatment. The ultimate goal is to find out if this combination of treatments can improve outcomes for patients with inoperable pleural mesothelioma.

The purpose of this study is to evaluate how effective Atezolizumab is in preventing the return of the disease after surgery. Participants in the study will receive either Atezolizumab or a placebo and will be monitored over a period of time to see how their disease progresses. The study will look at how long it takes for the disease to come back or for the patient to pass away from any cause. This is known as disease-free survival. Additionally, the study will monitor any side effects that occur during the treatment.

Throughout the study, participants will be regularly assessed by healthcare professionals to track their health and any changes in their condition. The study aims to provide valuable information on the potential benefits of Atezolizumab for patients with Malignant Pleural Mesothelioma, which could lead to improved treatment options in the future.

The purpose of the study is to understand if Tremelimumab can help people live longer when they have this type of cancer that cannot be removed by surgery. Participants in the study will receive either Tremelimumab or a placebo, and their health will be monitored over time to see how they respond to the treatment. The study will last for a period of up to 36 months, during which participants will have regular check-ups and tests to track their progress and any side effects they might experience.

Throughout the study, researchers will also look at other important factors, such as how the treatment affects the quality of life and any potential side effects. The study aims to provide valuable information about the safety and effectiveness of Tremelimumab for treating unresectable malignant mesothelioma, which could help improve future treatment options for this challenging condition.

The purpose of the study is to see how effective Talazoparib is in keeping the cancer from getting worse for at least six months after starting the treatment. Patients will first receive at least four cycles of chemotherapy before beginning the Talazoparib treatment. The study will follow patients to monitor their progress and see if the cancer remains stable. Some patients will receive a placebo instead of Talazoparib to compare the results.

Participants in the study will be divided into three groups, or cohorts, based on the type of mesothelioma they have. The study will last for several years, and during this time, patients will have regular check-ups and tests to track their health and the status of their cancer. The goal is to gather information that could help improve treatment options for people with mesothelioma in the future.

The purpose of the study is to evaluate how well this combination of medications works in treating the cancer before surgery. Participants will receive the treatment every three weeks for a total of three cycles. The study aims to see if the treatment can reduce the cancer to the point where no cancer cells are left in the tumor or nearby lymph nodes, which are small glands that help fight infection. This is known as a complete response. The study will also look at other outcomes, such as how long patients live without the cancer coming back and the overall safety of the treatment.

Throughout the study, researchers will monitor the participants’ health and any side effects they may experience. The study will help determine if this combination of medications can be a successful approach to treating Malignant Pleural Mesothelioma before surgery, potentially improving outcomes for patients with this type of cancer.

The purpose of this study is to see if this combination of treatments can be safely given to patients with malignant pleural mesothelioma. The study will involve patients receiving the photodynamic therapy first, followed by treatment with Nivolumab. The study will monitor patients to ensure that the treatments do not cause any unexpected or severe side effects. The study aims to include a small group of patients to test the feasibility of this treatment approach.

Throughout the study, researchers will collect information on how well the treatment works and how it affects the patients’ quality of life. This includes looking at how the cancer responds to the treatment and how long patients live without the disease getting worse. The study will also involve collecting samples from patients to better understand how the treatment affects the body and to look for markers that might predict how well the treatment works. The study is expected to continue for several years to gather enough information to determine the effectiveness and safety of this new treatment strategy.

The purpose of the study is to see if this new vaccine is safe and can be used effectively as a first treatment for patients with Malignant Pleural Mesothelioma, alongside standard chemotherapy. Participants in the study will receive the vaccine and chemotherapy over a period of time. The study will monitor how well the vaccine is tolerated and whether it can be successfully produced and administered.

Throughout the study, researchers will also look at how the disease responds to the treatment, including how long it takes for the disease to progress and how long patients live without the disease getting worse. Additionally, the study will examine the body’s immune response to the vaccine to understand if it helps the immune system fight the cancer more effectively.

The purpose of the study is to investigate how safe and feasible it is to add atezolizumab and WT1/DC vaccination to the usual chemotherapy for patients with this type of cancer. Participants in the study will receive a series of treatments over a period of time. This includes four cycles of chemotherapy combined with four treatments of atezolizumab and four vaccinations with WT1/DC. The study will monitor the safety of these treatments by observing any side effects that may occur during the treatment period and follow-up.

In addition to safety, the study will also look at how effective the treatment is in controlling the cancer. This includes measuring how well the cancer responds to the treatment, how long the response lasts, and the overall survival of the participants. The study will also assess the immune response generated by the WT1/DC vaccine. The trial is expected to continue until 2027, providing valuable information on the potential benefits and risks of this new treatment approach for patients with epithelioid malignant pleural mesothelioma.

Participants in the study will receive either the combination of nivolumab and ipilimumab with the UV1 vaccine or without it. The study will last for a period of up to 24 months, during which patients will receive regular treatments and be monitored closely by healthcare professionals. The study aims to determine if adding the UV1 vaccine to the treatment regimen improves outcomes for patients with this type of cancer.

Throughout the study, researchers will assess various aspects of the treatment’s effectiveness, such as how long patients live without the cancer getting worse and the overall survival rate. They will also monitor the patients’ quality of life and any side effects experienced during the treatment. This information will help determine the potential benefits and risks of using these treatments for malignant pleural mesothelioma.